Drugs that contain Finerenone

1. List of Kerendia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8436180 BAYER HLTHCARE Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
Apr, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 9, 2026
M Sep 1, 2025

NCE-1 date: July, 2025

Market Authorisation Date: 09 July, 2021

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic